Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

To Test or Not to Test?

Posted by Pranav Srivastava on Thu, Oct 01, 2015

Testing beyond BRCA in breast and ovarian cancers was the focus of a recent article in JAMA Oncology. The conclusion was:

In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. Multigene testing in this setting is likely to alter near-term cancer risk assessment and management recommendations for mutation-affected individuals across a broad spectrum of cancer predisposition genes.

Read More

Topics: oncology, cancer, Pranav Srivastava, testing, DNA

Subscribe to The Active Ingredient
SUBSCRIBE

Get 'THE ACTIVE INGREDIENT' Updates

Subscribe to receive email notifications whenever new blog posts are published.

×